Musculoskeletal Regenerative Medicine
- Establishing and spreading a novel meniscus regenerative medical device using an atelocollagen cell carrier
- Developing a novel hybrid musculoskeletal therapy combining musculoskeletal organ cells and atelocollagen cell carrier
- Developing a novel therapy for musculoskeletal regeneration using nanotechnology/three-dimensional mechanical stimulation culture system
- Developing software for promotion of health and dissemination of sports activities, and spreading healthcare promotion
Developing a novel therapy for musculoskeletal organ diseases using atelocollagen/three-dimensional mechanical stimulation culture system
As the super-aged society is coming, the extension of healthy life expectancy by maintaining musculoskeletal function has become a major issue for the independence of individuals and the suppression of medical costs and nursing workforce.
Orthopaedic Surgery and Medicine for Sports and Performing Arts at Graduate School of Medicine, Osaka University have conducted basic, translational, and clinical research on the treatment and prevention of various disorders of musculoskeletal organs (ligament, meniscus, cartilage, bone, tendon, skeletal muscle, etc.) and developed novel medical devices and regenerative medicine. We have obtained the patent for atelocollagen meniscus filling materials (patent No. 4915693 for cell culture carrier and patent No. 5909610 for collagen sponge). Also, we have currently started clinical research in humans as an advanced medical treatment designated by the Ministry of Health, Labour and Welfare after the nonclinical safety study and study in large animals.
Unlike planar culture in experiments, musculoskeletal organ cells have a three-dimensional structure in the body, and therefore, we have developed the original three-dimensional mechanical loading culture system and obtained the patent (the cell culture method using biomechanical stimulation loading and its device, patent No. 4116057 [P4116057]). We are conducting regenerative medicine research under the condition similar to the human body.
We have established a joint research course with Taisho Pharmaceutical Co., Ltd. that has been engaged in the development and marketing of various products for the health maintenance of musculoskeletal organs for many years and are aiming to market and spread atelocollagen filling material, a new regenerative medical device.
In the future, we will also aim to develop hybrid medicine in which the atelocollagen filling materials are combined with various types of musculoskeletal cells as well as novel regenerative therapy for musculoskeletal diseases using nanotechnology that we have been working on.
Medicine for Sports and Performing Art launched an innovative sports research base project for the 2020 Tokyo Olympics and Paralympics in 2015 with the Japan Sports Agency. We have been developing software for health promotion and dissemination of sports activities and promoting healthcare in addition to the activities as a base for building the cyber-physical system.
